Brian H. Ladle

1.3k total citations
25 papers, 709 citations indexed

About

Brian H. Ladle is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Brian H. Ladle has authored 25 papers receiving a total of 709 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Immunology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Brian H. Ladle's work include CAR-T cell therapy research (8 papers), Immunotherapy and Immune Responses (8 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Brian H. Ladle is often cited by papers focused on CAR-T cell therapy research (8 papers), Immunotherapy and Immune Responses (8 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Brian H. Ladle collaborates with scholars based in United States, Canada and Netherlands. Brian H. Ladle's co-authors include Elizabeth M. Jaffee, Todd D. Armstrong, R. Todd Reilly, Leisha A. Emens, Anne M. Ercolini, Jean-Pascal H. Machiels, Lukas W. Pfannenstiel, Joan Glick Bieler, Elizabeth A. Manning and Christopher Gamper and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The Journal of Experimental Medicine.

In The Last Decade

Brian H. Ladle

21 papers receiving 705 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brian H. Ladle United States	9	541	348	234	39	32	25	709
Alexandra B. Pucsek United States	4	557 1.0×	365 1.0×	194 0.8×	45 1.2×	18 0.6×	4	720
Jonathan J. Hodgins Canada	5	631 1.2×	530 1.5×	150 0.6×	55 1.4×	26 0.8×	7	803
E.Y. Woo United States	3	808 1.5×	463 1.3×	106 0.5×	42 1.1×	22 0.7×	7	948
Nathalie Fiegler Germany	7	539 1.0×	385 1.1×	133 0.6×	32 0.8×	18 0.6×	7	660
Koen A. Marijt Netherlands	10	480 0.9×	408 1.2×	151 0.6×	74 1.9×	35 1.1×	13	672
Alfons JM van den Eertwegh Netherlands	7	381 0.7×	420 1.2×	96 0.4×	107 2.7×	27 0.8×	8	546
Antonina Avanzi United States	6	368 0.7×	352 1.0×	109 0.5×	42 1.1×	14 0.4×	7	591
Francesca Besi Italy	11	497 0.9×	303 0.9×	231 1.0×	28 0.7×	30 0.9×	22	671
Amelia Roman Aguilera Australia	9	488 0.9×	366 1.1×	103 0.4×	53 1.4×	23 0.7×	9	642
Serena Tseng United States	5	470 0.9×	213 0.6×	166 0.7×	20 0.5×	42 1.3×	7	673

Countries citing papers authored by Brian H. Ladle

Since Specialization

Citations

This map shows the geographic impact of Brian H. Ladle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian H. Ladle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian H. Ladle more than expected).

Fields of papers citing papers by Brian H. Ladle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian H. Ladle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian H. Ladle. The network helps show where Brian H. Ladle may publish in the future.

Co-authorship network of co-authors of Brian H. Ladle

This figure shows the co-authorship network connecting the top 25 collaborators of Brian H. Ladle. A scholar is included among the top collaborators of Brian H. Ladle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian H. Ladle. Brian H. Ladle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oberoi, Sapna, et al.. (2025). Towards directed therapy for fusion-positive rhabdomyosarcoma. Pharmacology & Therapeutics. 276. 108931–108931.

Baretti, Marina, Allison M. Kirk, Brian H. Ladle, et al.. (2025). A therapeutic vaccine for fibrolamellar hepatocellular carcinoma.. Journal of Clinical Oncology. 43(16_suppl). 2503–2503.

Rahnama, Ruyan, Kathryn M. Lemberg, Jason Fixler, et al.. (2024). Brain Metastasis in Pediatric Patients with Osteosarcoma. Current Oncology. 31(11). 7014–7022. 1 indexed citations

Nakazawa, Mari, Amy Thomas, Jennifer N. Durham, et al.. (2024). Glutamine antagonist DRP-104 in combination with durvalumab in patients with advanced fibrolamellar carcinoma (FLC) following progression on prior anti-PD(L)1 therapy.. Journal of Clinical Oncology. 42(3_suppl). TPS573–TPS573. 5 indexed citations

Doucet, Michèle, Stephanie Glavaris, Sarah E. Powers, et al.. (2024). Abstract B054: Intratumoral injection with stimulator of interferon genes (STING) agonist increases T- and B-cell infiltrates in canine osteosarcoma. Cancer Research. 84(17_Supplement). B054–B054.

Chang, Leslie, Rohini Bhatia, Gayane Yenokyan, et al.. (2023). Impact of Consolidative Radiation on Overall and Progression-Free Survival in Pediatric, Adolescent, and Young Adult Metastatic Bone and Soft Tissue Sarcoma. International Journal of Radiation Oncology*Biology*Physics. 118(2). 474–484. 1 indexed citations

Parida, Sheetal, Sumit Siddharth, Himavanth R. Gatla, et al.. (2023). Gut colonization with an obesity-associated enteropathogenic microbe modulates the premetastatic niches to promote breast cancer lung and liver metastasis. Frontiers in Immunology. 14. 1194931–1194931. 23 indexed citations

Baretti, Marina, Brian H. Ladle, Julie M. Nauroth, et al.. (2023). 641 A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinoma. SHILAP Revista de lepidopterología. A733–A734. 1 indexed citations

Hensel, Jonathan A., et al.. (2022). Adoptive Cellular Therapy for Pediatric Solid Tumors: Beyond Chimeric Antigen Receptor-T Cell Therapy. The Cancer Journal. 28(4). 322–327. 2 indexed citations

10.

Araujo, Dejka M., Brian H. Ladle, Benjamin Powers, et al.. (2022). ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296].. Journal of Clinical Oncology. 40(16_suppl). TPS2681–TPS2681. 3 indexed citations

11.

Liu, Tingting, et al.. (2021). Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma. Molecular Case Studies. 7(4). a006064–a006064. 18 indexed citations

12.

Stachelek, Gregory C., John A. Ligon, Jennifer Vogel, et al.. (2021). Predictors of Recurrence and Patterns of Initial Failure in Localized Ewing Sarcoma: A Contemporary 20-Year Experience. Sarcoma. 2021. 1–7. 8 indexed citations

13.

Parida, Sheetal, Sumit Siddharth, Guannan Wang, et al.. (2021). Abstract PS19-02: Gut pathogen, Bacteroides fragilis promotes breast cancer liver and lung metastasis. Cancer Research. 81(4_Supplement). PS19–2. 1 indexed citations

14.

Kim, Victoria M., Kevin C. Soares, Nita Ahuja, et al.. (2020). Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer. JCI Insight. 5(9). 24 indexed citations

15.

Ladle, Brian H., et al.. (2019). T-cell receptor signal strength and epigenetic control of Bim predict memory CD8+ T-cell fate. Cell Death and Differentiation. 27(4). 1214–1224. 19 indexed citations

16.

Ladle, Brian H., Alexandra B. Pucsek, Azeb Haile, et al.. (2016). De novo DNA methylation by DNA methyltransferase 3a controls early effector CD8⁺T-cell fate decisions following activation. Proceedings of the National Academy of Sciences. 113(38). 10631–10636. 117 indexed citations

17.

Thomas, Rajan M., Christopher Gamper, Brian H. Ladle, Jonathan D. Powell, & Andrew D. Wells. (2012). De Novo DNA Methylation Is Required to Restrict T Helper Lineage Plasticity. Journal of Biological Chemistry. 287(27). 22900–22909. 66 indexed citations

18.

Le, Dung T., Brian H. Ladle, Timothy Lee, et al.. (2010). CD8⁺Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti‐tumor response. International Journal of Cancer. 129(3). 636–647. 18 indexed citations

19.

Murata, Satoshi, Brian H. Ladle, Peter Kim, et al.. (2006). OX40 Costimulation Synergizes with GM-CSF Whole-Cell Vaccination to Overcome Established CD8+ T Cell Tolerance to an Endogenous Tumor Antigen. The Journal of Immunology. 176(2). 974–983. 79 indexed citations

20.

Ercolini, Anne M., Brian H. Ladle, Elizabeth A. Manning, et al.. (2005). Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response. The Journal of Experimental Medicine. 201(10). 1591–1602. 317 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact